SANA

$3.55-$0.12 (-3.27%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$1.1B

299M shares

52-week range

$2.61 – $6.55

24% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change$-16.40

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-0.61	$-0.71–$-0.53	—	6
2027	$7M	—	$-0.58	$-0.67–$-0.46	—	5
2028	$20M	+184.9%	$-0.59	$-0.72–$-0.39	—	6
2029	$5M	-74.9%	$-0.68	$-0.68–$-0.68	—	3

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-11	$-0.15	$-0.22	-49.8%
2026-05-11	$-0.15	$-0.14	+6.7%
2026-03-03	$-0.13	$-0.16	-23.1%
2025-11-06	$-0.18	$-0.15	+16.7%
2025-08-11	$-0.20	$-0.16	+20.0%
2025-05-08	$-0.22	$-0.20	+9.1%
2025-03-17	$-0.25	$-0.23	+8.0%
2024-11-08	$-0.26

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
SANASana Biotechnology, Inc.	$3.55	-3.27%	$988M	—
DNTHDianthus Therapeutics, Inc.	$115.96	+5.80%	$6.5B	—
INBXInhibrx Biosciences Inc.	$88.37	-8.91%	$1.3B	—
KODKodiak Sciences Inc.	$41.35	+3.43%	$2.6B	—
NKTRNektar Therapeutics	$73.02	-3.82%

Sana Biotechnology, Inc. Common Stock

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.

www.sana.com

Employees: 142
IPO / List date: Feb 4, 2021
HQ: SEATTLE, WA

Held by traders on TradeandTell

No one on the platform currently holds SANA.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	1,451,200	$4.2M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded SANA yet.

$SANA chatter on StockTwits

Bob Knob@cta7978Bullish1h
$SANA Back in heavy.
View on StockTwits ↗
Jerry Malone@JerryMalone322h
@NotHopeJustFacts @Jjpratt19 A lot hinges on Fusogen. If Lymphoma data are strong, it triggers a second phase 1 trial in multiple myeloma next summer. Also, a multi-billion dollar partnership for Fusogen with big pharma would be in play. So, whether (and how much) $SANA dilutes the shareholders will be greatly impacted by Fusogen and any Partnership dollars.
View on StockTwits ↗
Suwoo@Y007Bearish2h
$SANA
View on StockTwits ↗
JL@NotHopeJustFacts5h
$SANA $10M per month to operate while doing research as any high schooler ? this will take many YEARS in plural and thus many dilutions before they tell you that didn't make expectations
View on StockTwits ↗
Sam@LoveRetailFroth6h
$RXRX Good Morning ☕️ I am a marathon 🏃‍♂️. $ARBE $SANA $VIVO
View on StockTwits ↗
Ruhalth@brut_2_37h
$SANA BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7
View on StockTwits ↗
robert@retireddprof9h
$SANA FYI a possible future successful encapsulation approach https://dx.doi.org/10.1038/s41551-026-01775-8
View on StockTwits ↗
Kamikazekid@PoshfoxBullish2d
$SANA hmm. All these up days got us close to the 70%rsi resistance. Needed a down day to to push it higher. So after hitting a new 1 month high on another big buy, we close the last second .02 down. Almost like something or someone is shepherding this stock higher.
View on StockTwits ↗
Humean Rgmnt@BBraggHillBoysBullish2d
$SANA I'm already up 8% on this bullish confirmation; I'm not trimming yet.
View on StockTwits ↗
Jerry Malone@JerryMalone322d
@mirko_papuga @Y007 i could not care less at this point whether Mayo ponies up another $25 million at $3.33 a share or whether $SANA goes the ATM route. It is “six of one, a half-dozen of the other” as far as I am concerned. The unknown is why Mayo wanted an option to purchase 140 days down the road in the first place. Was August 31 the date by which Sana expected to file the IND? Who the heck knows?
View on StockTwits ↗
Jerry Malone@JerryMalone322d
@Y007 $SANA has not stalled on it. It is 100% on track. There are 4.5 months left in 2027 for crying out loud. I feel like I am in an insane asylum reading these posts.
View on StockTwits ↗
Sam@LoveRetailFrothBullish2d
$SANA SG-293 Yuge. Primary market, NHL -15 billion. Secondary market- Autoimmune diseases - 150 billion 🚀🍺
View on StockTwits ↗
Suwoo@Y007Bearish2d
$SANA Mayos involvement only reason this company made sense and now with its disappointing ER major red flags have emerged… 25 Million is pocket change to Mayo.. The fact that they are letting the clock run out all the way to the August 31 deadline proves this isn't about the money… The primary goal for Sana this year was to cleanly file their IND application for their lead diabetes project. By stalling on that application, Sana has missed a critical operational checkpoint… Sana board is in complete dissent as they have been keeping its lights rolling by aggressively printing new shares and dumping them onto retail investors via their At-The-Market facility. Mayo will not throw good money after bad if they see that management is using dilution to stay afloat while their actual drug development timeline is moving backwards. Finally their main project is getting absolutely crushed in its race against a Goliath in Vertex Mayo walks away this thing is a wrap by September
View on StockTwits ↗
David@Lowboy66Bullish3d
$SANA Mmmmmmmmm
View on StockTwits ↗
Sam@LoveRetailFrothBullish3d
$SANA 🚀
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.